Psilocybin and SSRIs: Do You Have to Stop Your Antidepressant?

This is the single most common question we get about natural medicine, and the honest answer is that it is actively unsettled.

For most of the past decade, the standard protocol was simple: taper off your antidepressant two weeks before a psilocybin session. Most clinical trials required it. Most facilitators repeated it. Most of what you’ll find online still says it. But the evidence supporting that rule turned out to be thinner than the confidence with which it was stated, and a wave of recent research has made a serious case that the taper may be unnecessary — and, for some people, actively harmful.

What follows is both sides, as fairly as we can put them. We’re not going to resolve it for you, because it isn’t resolved, and because this is a decision that belongs to you and your prescriber. Facilitators in Colorado are not prescribers and cannot direct a medication change. What we can do is make sure you walk into that conversation knowing what’s actually been studied.

Two questions that get conflated

Almost all of the confusion here comes from collapsing two separate questions into one.

Is it dangerous to combine them? This one is largely settled, and the answer is reassuring.

Will the psilocybin still work? This one is genuinely open, and it’s where the real disagreement lives.

People hear “you have to stop your SSRI” and assume it’s a safety rule. Mostly, it isn’t. It’s an efficacy rule — and the evidence behind it has gotten shakier.

The safety question

The fear is serotonin syndrome: psilocybin acts on serotonin receptors, SSRIs raise serotonin availability, and stacking them sounds like it should be dangerous.

The data don’t support that concern at therapeutic doses. A 2025 scoping review in the Journal of Psychopharmacology examined thirteen safety studies of classic psychedelics combined with antidepressants; ten showed no signs of serotonin toxicity. Pretreatment with escitalopram at 20mg produced a safety profile comparable to placebo. Adverse events that did occur — headache, nausea, transient blood pressure elevation — were mild and short-lived.

The one case in the literature often cited as a counterexample involved ayahuasca rather than psilocybin, and the reaction was attributed to the MAOIs in the brew, not to the SSRI.

That distinction matters, because MAOIs and lithium are genuine hard stops — for different and much more serious reasons, covered in our post on psilocybin contraindications. SSRIs and SNRIs are not in that category.

The case for tapering

The strongest argument for tapering isn’t safety. It’s that your antidepressant may blunt the experience enough to waste the session.

There’s real evidence for this. A 2023 Johns Hopkins survey study analyzed 611 reports from people who took psilocybin while on an antidepressant. Weaker-than-expected effects were reported by 47% of those on SSRIs and 55% of those on SNRIs — compared with 29% on bupropion, which isn’t serotonergic. The mechanism is plausible: sustained SSRI use downregulates and desensitizes the 5-HT2A receptor that psilocybin acts on.

If you’re investing significant time and money in a session, a coin-flip chance of a muted experience is not a trivial risk.

But the same study contains a finding that complicates the standard protocol considerably. Among people who had discontinued their antidepressant, attenuation remained common — the probability stayed elevated at roughly 30% and didn’t meaningfully drop until somewhere in the three-to-six-month range. Excluding fluoxetine, which has an unusually long half-life, didn’t change the picture much.

Read that carefully. If receptor changes take months to normalize, then a two-week washout — the protocol most trials used and most people are told to follow — may not accomplish the thing it exists to accomplish. It asks people to absorb the full cost of stopping their medication without reliably delivering the benefit.

The case against tapering

Two lines of evidence push the other direction.

The first is that psilocybin appears to work in people who stay on their medication. A 2023 open-label trial published in Neuropsychopharmacology gave a single 25mg dose of psilocybin to people with treatment-resistant depression who remained on their SSRI throughout. At three weeks, 42% met response criteria and 42% met remission criteria — modestly better than the same research group’s earlier trial in which SSRIs were withdrawn (37% response, 29% remission). It was a small, open-label study and not a head-to-head comparison, so it can’t settle the question. But it’s difficult to reconcile with the claim that staying on an SSRI makes psilocybin therapy pointless.

The 2025 scoping review found the same pattern more broadly: eight studies showed no significant change in acute subjective effects from concomitant antidepressant use. The attenuation signal is real but far less consistent than the survey data alone suggests — and survey respondents who expected a blunted trip may not be the most neutral judges of whether they had one.

The second argument is about what tapering actually costs. Antidepressant discontinuation is not a neutral act. Roughly 56% of people experience discontinuation syndrome, and stopping carries about a 40% increased risk of depressive relapse. The review notes a case in which someone who discontinued duloxetine before a second psilocybin dose experienced worsening depression, anxiety, and suicidality.

Consider the sequencing there. Someone tapers off the medication holding them stable, becomes more symptomatic and potentially more suicidal, and then — at their most vulnerable — walks into a demanding, emotionally intense psychedelic session. That is a genuinely risky arrangement, and it’s the one the conventional protocol produces.

There’s also an access argument. Of 100 registered psilocybin studies, 84 exclude people taking SSRIs. Since SSRIs are among the most-prescribed medications in the country, the rule doesn’t just shape protocols — it shapes who gets studied and who gets treated. The review’s authors conclude that maintaining antidepressants could substantially expand access without compromising safety or efficacy.

So where does that leave you?

Somewhere honest: this is a real trade-off with no clean answer, and the right call depends on specifics no article can know.

The factors that actually matter are how stable you are right now, how well the medication is working, how you’ve responded to dose changes in the past, which medication and dose you’re on, whether you have prescriber support to taper and to restart, and how much a possibly-muted session would cost you in money and time.

Questions worth bringing to your prescriber:

• Is my depression stable enough that a taper is reasonable to attempt at all?
• What’s my history with discontinuation — have I tried before, and what happened?
• If we taper and I destabilize, what’s the plan, and how quickly can we restart?
• Given the evidence that attenuation may persist for months, does a short washout actually buy anything in my case?
• Would you be comfortable with me proceeding while staying on it?

That last question is worth asking directly. A fair number of prescribers, given the current evidence, will say yes.

What about other antidepressants?

SNRIs (venlafaxine, duloxetine) behave much like SSRIs, with a slightly stronger attenuation signal in the survey data and the same underlying uncertainty.

Bupropion isn’t serotonergic and shows the lowest attenuation rate of the common antidepressants. Generally the least complicated situation.

Mirtazapine directly antagonizes the 5-HT2A receptor psilocybin works through — this is the clearest pharmacological case for a pre-session change, and it’s usually tapered.

Trazodone has at least one case report of the acute experience being eliminated entirely.

Tricyclics may attenuate the experience and warrant extra attention to blood pressure and heart rate.

MAOIs and lithium are different in kind — firm contraindications, not taper conversations. See psilocybin contraindications for why.

Four things not to do

Don’t taper on your own. Not slowly, not carefully, not “just to see.” Antidepressant discontinuation has a real symptom profile and a real relapse risk, and it needs to be supervised by whoever prescribes it.

Don’t taper in order to qualify. No responsible program requires you to stop a psychiatric medication as a condition of being accepted. If one does, that tells you something about how it makes decisions. The medication question should be settled on its own clinical merits, then the session gets planned around the answer.

Don’t leave it off your intake. Every medication gets reviewed during screening, including the ones you assume are irrelevant. Omitting something to avoid a complication is how complications happen.

Don’t stop cold turkey before a session. Of all the available options, abruptly discontinuing shortly before an intense emotional experience is the one with the worst risk profile. If a taper is the plan, it should be gradual, supervised, and well ahead of any scheduled date.

The short version

Combining psilocybin with an SSRI or SNRI appears to be safe. Whether it blunts the experience is unresolved — survey data says often, trial data says frequently not, and the receptor changes behind the concern may take months rather than weeks to reverse, which undercuts the standard two-week washout on its own terms.

What’s changed is that “you have to stop your antidepressant” is no longer a defensible blanket statement. It’s a case-by-case decision, it belongs to you and your prescriber, and it’s reasonable to arrive at it having read the same evidence they have.

---

Have questions about your specific medications? Get in touch or book a free 15-minute consultation — we’ll talk through what your situation would involve, including what to raise with your prescriber. You may also want to read is psilocybin therapy right for you, how psilocybin therapy fits with other treatments, or how to prepare for a journey.

This post is educational and is not medical advice. Never start, stop, or change a psychiatric medication without consulting your prescribing provider.